stockrowLatest quarter
Oruka reported a diluted loss per share of −$0.55 for the second quarter, compared with −$0.46 a year earlier. Its adjusted loss per share was −$0.55, below the consensus estimate of −$0.49. The company’s free cash flow was −$33.1 million, compared with −$23.2 million a year earlier. Oruka reported about $1.1 billion in cash, cash equivalents and marketable securities at the end of the quarter.
Oruka is a clinical-stage biotechnology company developing antibody medicines for psoriasis and other inflammatory diseases. Its lead candidate, ORKA-001, is designed for psoriasis and targets a protein involved in inflammation. Oruka is also studying ORKA-002 for psoriasis and plans to study it for hidradenitis suppurativa, a skin disease that can cause painful nodules and abscesses. The company has not generated revenue from product sales and has primarily funded operations through securities issuances.
| Q2 FY2026 | Q2 FY2025 | Change | |
|---|---|---|---|
| Diluted EPS | −$0.55 | −$0.46 | — |
| Free cash flow | −$33.1 million | −$23.2 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$0.55 | −$0.49 | Missed by 12.2% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
An earnings call for Oruka’s latest quarter is not available, so management’s call commentary cannot be reported.
Guidance
Oruka’s management guidance is not available. Separately, the company expects its cash to fund operations through an ORKA-001 biologics license application filing. Oruka also expects to share longer-term EVERLAST-A trial results in December.